Stocky turns companies like Allogene Therapeutics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Allogene Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Directors make major company decisions; shareholders voted to keep Deborah Messemer, Vicki Sato, and Owen Witte leading the board.
Allogene can now sell up to $500 million in stock, bonds, or other securities to raise money when needed.
New CEO will lead company strategy and operations; David Chang replaced after previous tenure.
Quarterly earnings update shows how the company performed during the first three months of 2026.
Allogene ended a $40 million deal granting exclusive therapy rights in Asia; reduces future milestone payments.
Company selling massive amount of stock through Goldman Sachs and other underwriters to raise capital.
Updated prospectus allows Allogene flexibility to issue stock, bonds, or warrants over time as needed.
Stocky reads Allogene Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Allogene Therapeutics, Inc.'s most recent tracked filing was a 8-K on 22 Jun 2026: Stockholders elect three directors to three-year terms.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.